A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
JF Seymour, DW Kim, E Rubin, A Haregewoin, J Clark, P Watson, T Hughes, I Dufva, JL Jimenez, F-X Mahon, P Rousselot, J Cortes, G Martinelli, Cristina Papayannidis, A Nagler, FJ Giles
Blood Cancer Journal | NATURE PUBLISHING GROUP | Published : 2014
This study was sponsored by Merck & Co., Inc., Whitehouse Station, NJ, USA. Writing and editorial assistance was provided by Jennifer Granit, PhD, Integrus Scientific, and was funded by Merck & Co., Inc.